Celecoxib CV risk increased at higher dosages

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2008年 / 1197卷 / 1期

关键词：

Public Health; Adverse Event; Placebo; Cardiovascular Risk; Randomise Control Trial;

D O I：

10.2165/00128415-200811970-00007

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：3 / 3

相关论文

共 50 条

[1] Celecoxib: no increased risk of CV events
Reactions Weekly, 2002, 892 (1) : 4 - 4
[2] Increased CV risks with long-term celecoxib and rofecoxib
Reactions Weekly, 2006, 1111 (1) : 4 - 4
[3] Celecoxib: increased risk of myocardial infarction
Reactions Weekly, 2006, 1092 (1) : 4 - 4
[4] Celecoxib/rofecoxib: increased risk of thrombosis?
Reactions Weekly, 2001, 876 (1) : 5 - 5
[5] Increased dyspepsia risk with high NSAID dosages
Reactions Weekly, 2003, 970 (1) : 5 - 5
[6] Higher dosages of metformin increase risk of diabetic retinopathy
Reactions Weekly, 2025, 2047 (1) : 9 - 9
[7] Increased CV risk with rosiglitazone but not pioglitazone
Reactions Weekly, 2009, 1276 (1) : 2 - 2
[8] Celecoxib safety review recommends lower dosages
Reactions Weekly, 2016, 1598 (1) : 2 - 2
[9] Lowest effective dosages of celecoxib need to be determined
Reactions Weekly, 2005, 1073 (1) : 3 - 3
[10] Celecoxib is not associated with an increased risk of thromboembolic events.
Whelton, A
Faich, G
Lefkowith, J
ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S136 - S136

← 1 2 3 4 5 →